12 completed, 6 terminated, 5 unknown, 3 recruiting. 11 Phase 2, 6 Not applicable, 5 Phase 3, 1 Phase 1, 1 Phase 4.
Follow digital ulcers: new trials by email Literature Review of digital ulcers trials Research Report on digital ulcers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers L608, Placebo - Systemic Sclerosis | Phase 2 | Not yet recruiting | Pharmosa Biopharm Inc. | 40 | 2027-02-01 | 2026-11-09 |
| Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis Blood sampling, nailfold capillaroscopy - Systemic Sclerosis, Pulmonary Arterial Hypertension | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 60 | 2026-09-01 | 2026-07-21 |
| Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis Diosmin, Placebo - Scleroderma, Systemic, Digital Ulcer | Not applicable | Recruiting | Primus Pharmaceuticals | 45 | 2025-05-02 | 2026-11-10 |
| Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis TOP-N53, Sildenafil, TOP-N53 vehicle - Digital Ulcers in Systemic Sclerosis | Phase 2 | Recruiting | Topadur Pharma AG | 15 | 2025-02-04 | 2026-10-01 |
| Hand Disability In Systemic Sclerosis - Digital Ulcers Systemic Sclerosis (SSc), Digital Ulcer | Enrolling by invitation | Pamukkale University | 72 | 2024-10-24 | 2026-03-19 | |
| Co-designing Digital Ulcers Opportunities With Patients and Clinicians No intervention - Scleroderma, Scleroderma Associated Digital Ulcer | Unknown | King's College London | 25 | 2023-06-01 | 2023-03-27 | |
| Effectiveness of the EmoLED Medical Device in the Healing of Digital Ulcers in Patients With Scleroderma. EmoLED treatment, current Standard of Care - Ulcer, Acral Nevus | Not applicable | Terminated | Emoled | 36 | 2022-04-22 | 2024-06-07 |
| Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis Rheopheresis treatment, Intravenous Infusion - Systemic Sclerosis, Raynaud Phenomenon | Not applicable | Unknown | Peter Korsten | 30 | 2022-02-28 | 2022-03-23 |
| Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease. Scleroderma, Digital Ulcer | Unknown | Elpen Pharmaceutical Co. Inc. | 300 | 2022-01-01 | 2023-11-01 | |
| Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis Mesenchymal stromal cells, Placebo - Systemic Sclerosis, Digital Ulcer | Phase 1 / Phase 2 | Recruiting | UMC Utrecht | 20 | 2021-10-06 | 2025-09-10 |
| Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers Autologous fat grafting, Sham procedure - Systemic Sclerosis, Digital Ulcer | Not applicable | Unknown | ASST Gaetano Pini-CTO | 46 | 2017-07-18 | 2018-01-25 |
| Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis Botulinum toxin type B (2500 units / vial), Physiological saline - Systemic Sclerosis Patients With Digital Ulcers | Phase 2 | Completed | Gunma University | 10 | 2016-12-12 | 2020-05-14 |
| ADMSCs for the Treatment of Systemic Sclerosis injection of autologous stromal vascular fraction - Systemic Sclerosis | Not applicable | Completed | The Catholic University of Korea | 7 | 2016-10-25 | 2018-01-25 |
| Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis Bosentan group - Systematic Sclerosis, Digital Ulcer | Completed | Elpen Pharmaceutical Co. Inc. | 148 | 2016-09-30 | 2019-07-05 | |
| Riociguat in Scleroderma Associated Digital Ulcers Riociguat, Placebo - Scleroderma, Digital Ulcers | Phase 2 | Completed | Dinesh Khanna, MD, MS | 17 | 2016-09-01 | 2019-09-24 |
| CSL Behring Sclero XIII Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride - Systemic Sclerosis | Phase 2 | Unknown | University College, London | 26 | 2015-09-01 | 2016-05-30 |
| Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study Calcium Channel Blockers, Phosphodiesterase Inhibitors, Endothelin receptor blocker - Raynaud Disease, Systemic Sclerosis | Terminated | Seoul National University Hospital | 71 | 2015-01-01 | 2020-11-10 | |
| Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients Macitentan 3 mg, Macitentan 10 mg, Placebo - Digital Ulcers | Phase 3 | Terminated | Actelion | 265 | 2011-12-01 | 2025-02-04 |
| Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients macitentan 3mg, macitentan 10mg, placebo - Systemic Sclerosis, Ulcers | Phase 3 | Completed | Actelion | 289 | 2011-12-01 | 2015-01-06 |
| Bosentan in Systemic Sclerosis Bosentan - Systemic Sclerosis, Digital Ulcers | Phase 4 | Completed | Actelion | 18 | 2011-03-31 | 2026-06-03 |
Showing 20 of 29. Sign in to see all of them.
Scleroderma, Systemic (20) · Scleroderma, Diffuse (11) · Raynaud Disease (4) · Diabetes Complications (2) · Diabetic Foot (2) · Foot Ulcer (2) · Gangrene (2) · Ulcer (2) · Vascular Diseases (2) · Autoimmune Diseases (1) · Pulmonary Arterial Hypertension (1) · Sclerosis (1)
Skin Diseases (28) · Skin and Connective Tissue Diseases (28) · Connective Tissue Diseases (26) · Cardiovascular Diseases (8) · Scleroderma, Systemic (6) · Vascular Diseases (6) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Embolism and Thrombosis (4) · Livedoid Vasculopathy (4) · Peripheral Vascular Diseases (4) · Skin Diseases, Vascular (4) · Thrombosis (4) · Diabetes Mellitus (2) · Diabetic Angiopathies (2)
Bosentan (3) · 2-(2-(4-chlorophenyl)ethoxy)adenosine (2) · macitentan (2) · Blood Specimen Collection (1) · Calcium Channel Blockers (1) · Diosmin (1) · Factor VIII (1) · Factor XIII (1) · Iloprost (1) · Infusions, Intravenous (1) · Microscopic Angioscopy (1) · Nifedipine (1) · Phosphodiesterase Inhibitors (1) · Prostaglandins (1) · Saline Solution (1)
Actelion (6) · Charite University, Berlin, Germany (2) · Elpen Pharmaceutical Co. Inc. (2) · Pfizer (2) · ASST Gaetano Pini-CTO (1) · Dinesh Khanna, MD, MS (1) · Emoled (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Gunma University (1) · King's College London (1) · Pamukkale University (1) · Peter Korsten (1) · Pharmosa Biopharm Inc. (1) · Primus Pharmaceuticals (1) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (1)
Germany (5) · United States (5) · Italy (4) · Canada (3) · Greece (3) · Netherlands (3) · United Kingdom (3) · Czechia (2) · France (2) · India (2) · South Korea (2) · Switzerland (2) · Turkey (Türkiye) (2) · Australia (1) · Austria (1)
James Seibold, MD (2) · Aman Sharma, MD (1) · Christopher Denton, PhD (1) · Darshan S Bhakuni, MD (1) · Dinesh Khanna, MD (1) · Dr. Gabriela Riemekasten, MD (1) · Gabriela Riemekasten, MD (1) · Jung Hee Koh, MD (1) · Marianne Verhaar, MD, PhD (1) · Nicoletta Del Papa, MD (1) · Parasar Ghosh, MD, DM (1) · Peter Korsten, Dr. med. (1) · Robert L. Rolleri, Pharm.D. (1) · Sei-ichiro Motegi (1)
PMID 27163986, PMID 18634152, PMID 20805294, PMID 30127049, PMID 30616671, PMID 31481106, PMID 33765691, PMID 35492333, PMID 37929840
2014 (1), 2015 (1)